Literature DB >> 8502996

Relation of phenotype evolution of HIV-1 to envelope V2 configuration.

M Groenink1, R A Fouchier, S Broersen, C H Baker, M Koot, A B van't Wout, H G Huisman, F Miedema, M Tersmette, H Schuitemaker.   

Abstract

Biological variability of human immunodeficiency virus type-1 (HIV-1) is involved in the pathogenesis of acquired immunodeficiency syndrome (AIDS). Syncytium-inducing (SI) HIV-1 variants emerge in 50 percent of infected individuals during infection, preceding accelerated CD4+ T cell loss and rapid progression to AIDS. The V1 to V2 and V3 region of the viral envelope glycoprotein gp120 contained the major determinants of SI capacity. The configuration of a hypervariable locus in the V2 domain appeared to be predictive for non-SI to SI phenotype conversion. Early prediction of HIV-1 phenotype evolution may be useful for clinical monitoring and treatment of asymptomatic infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8502996     DOI: 10.1126/science.8502996

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  90 in total

1.  Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia.

Authors:  F Voulgaropoulou; B Tan; M Soares; B Hahn; L Ratner
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Pattern of gp120 sequence divergence linked to a lack of clinical progression in human immunodeficiency virus type 1 infection.

Authors:  W K Wang; M Essex; M F McLane; K H Mayer; C C Hsieh; H G Brumblay; G Seage; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

5.  HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle.

Authors:  R A Fouchier; M Brouwer; N A Kootstra; H G Huisman; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  Syncytium induction in primary CD4+ T-cell lines from normal donors by human immunodeficiency virus type 1 isolates with non-syncytium-inducing genotype and phenotype in MT-2 cells.

Authors:  B J Todd; P Kedar; J H Pope
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

8.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.